Allurion has entered a pilot collaboration agreement with Medtronic, to expand access to Allurion’s AI-powered weight loss programme through a sales agency agreement in the Central and Eastern Europe, Middle East, and Africa (CEMA) region. The 12-month sales agency agreement enables Allurion to offer the Allurion Balloon and accelerate utilisation of the Allurion Iris Artificial Intelligence (AI) Platform in the management of bariatric surgery patients by leveraging Medtronic channels during the collaboration.
The Allurion Program combines the Allurion Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss with the Allurion Virtual Care Suite, a remote patient monitoring solution powered by the Allurion Iris AI Platform and the company’s proprietary behaviour change programme.
The Allurion Virtual Care Suite is also available to providers as a standalone product to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.
In February 2023, Allurion announced its intention to go public via a business combination with Compute Health. Medtronic is currently an investor in Compute Health, and this agreement builds upon that existing relationship.
"We are thrilled to join forces with Medtronic to expand access to our weight loss program. Medtronic has exceptional distribution capabilities across a number of different channels that can augment our base business,” said Dr Shantanu Gaur, Allurion’s Founder and CEO. “We also believe this partnership will help accelerate adoption of our Iris AI Platform as a standalone offering to streamline the management of patients undergoing bariatric surgery and potentially improve outcomes, further cementing our position as a leader in AI and weight management.”